Shares of oral monoclonal antibody developer Dice Therapeutics, Inc. (DICE) have fallen over 20% since an October 2022 secondary offering priced at $36.50. The capital raise followed very encouraging ...
Dice: 60% More Tech Professionals Have Lost Jobs in 2024 Your email has been sent Views on tech growth in the current economy Areas of focus AI surging, cloud technology declining What tech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results